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http://dx.doi.org/10.1016/j.jacl.2014.0BACKGROUND: Statin intolerance has been a major limitation in the use of statins, especially at
higher doses. New effective treatments are needed for lowering low-density lipoprotein cholesterol
(LDL-C) in patients who cannot tolerate daily statin doses.
OBJECTIVE: ODYSSEYALTERNATIVE (NCT01709513) evaluates efficacy and safety of alirocu-
mab, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody, in patients with
well-documented statin intolerance and moderate to very high cardiovascular risk.
METHODS: This is a phase 3, multicenter, randomized, double-blind, double-dummy study in statin-
intolerant patients. Intolerance was defined as inability to take at least 2 different statins because of
muscle-related adverse events (AEs), 1 at the lowest approved starting dose. Patients first received
single-blind subcutaneous and oral placebo for 4 weeks, and were withdrawn if they developed
muscle-related AEs after the placebo treatment. Continuing patients were randomized (2:2:1 ratio)
to alirocumab 75 mg self-administered via single 1 mL prefilled pen every 2 weeks or ezetimibe
10 mg/day or atorvastatin 20 mg/day (statin rechallenge), for 24 weeks. Alirocumab dose was increased
to 150 mg every 2 weeks (also 1 mL) at week 12 depending on week 8 LDL-C level. The primary
endpoint is percent change in LDL-C from baseline to week 24 by intent-to-treat analysis. Muscle-
related AEs were assessed by spontaneous patient reports and clinic queries.
RESULTS: A total of 314 patients have been randomized.
CONCLUSIONS: This is the first and only study of a new class of LDL-C–lowering agents in pa-
tients selected with a rigorously documented intolerance to statins, using a placebo run-in and statin
control arm.
 2014 National Lipid Association. Open access under CC BY-NC-ND license.nofi and Regeneron Pharmaceuti-
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Moriarty et al Alirocumab for statin intolerance: trial design 555Statins are the most effective medications presently The ODYSSEYALTERNATIVE study (NCT01709513)
available to reduce low-density lipoprotein cholesterol
(LDL-C; expected reductions of 30%–50%) and thereby
reduce cardiovascular (CV) risk.1 However, statin intoler-
ance, broadly defined as the inability to tolerate statin ther-
apy, usually because of muscle adverse events (AEs), has
been a major limitation in the use of statins.2–4 Yet
currently, there are no non-statin drugs that lower LDL-C
as effectively as statins, and many of the statin alternatives
are poorly tolerated.1–3
Many patients in clinical practice (approximately
10%–25%) are not able to tolerate statins either at all or
at a dose sufficient to effectively lower their LDL-C to
recommended goal levels.2,3,5–7 Approximately 13% of
both statin- and placebo-treated patients reported muscle
complaints in randomized controlled statin trials8; however,
this does not provide a reliable indication of prevalence
because most of these trials excluded patients with a his-
tory, or increased risk, of statin intolerance. Furthermore,
there has been substantial variability in how statin intoler-
ance has been assessed across these studies.8 Well-
controlled, randomized trials in statin-intolerant patients
are lacking, although the Effect of Statin Medications on
Muscle Performance study reported that more subjects
receiving atorvastatin 80 mg daily experienced muscle
symptoms compared with placebo (9.4% vs 4.6%).9
Alirocumab is a fully human monoclonal antibody that
specifically binds to proprotein convertase subtilisin/kexin
type 9.10,11 In 3 phase 2 studies, it was shown to reduce
LDL-C by approximately 40 to 70% when administered as
a 50- to 150-mg dose every 2 weeks (Q2W) on top of back-
ground statin therapy (compared with reductions of
5%–10% with placebo) and was well-tolerated, with self-
limiting, mild injection site reactions as the most common
AE.12–14 In the 2 phase 2 studies on stable background statin
dose, muscle disorders were reported in 6% of patients who
received alirocumab 50 to 150 mg Q2W (n 5 108) and 7%
of placebo patients (n 5 46).12,14 In the other phase 2 study
(n 5 30 or 31 per arm),13 patients were randomized to in-
crease their background atorvastatin dose from 10 to
80 mg/day plus either placebo or alirocumab, or remain on
atorvastatin 10 mg/day plus alirocumab; 17 to 19% of pa-
tients who received atorvastatin 80 mg experienced a
muscle-related AE, compared with 6% who remained on
atorvastatin 10 mg (with concomitant alirocumab).13 In a
phase 3 study, a decrease in LDL-C of 54% (on-treatment)
was reported at week 24 when alirocumab 75 mg Q2W
was given as monotherapy (n5 51; dose could be increased
to 150 mg Q2W at week 12 based on LDL-C), compared
with a 17% reduction with ezetimibe (n 5 50).15 In this
monotherapy study, a similar proportion of AEs were re-
ported with alirocumab (69% of patients) and ezetimibe
(78% of patients), with muscle-related AEs reported in 4%
of patients in both treatment arms.15 These results demon-
strate the efficacy of alirocumab when administered as either
combination therapy or monotherapy, the latter being rele-
vant for patients with statin-intolerance.compares the efficacy and safety of alirocumab vs ezeti-
mibe in statin-intolerant patients. The definition of statin
intolerance centers on myalgia, as this is considered to be
the primary side effect limiting statin use.2,3,16 Intolerance
is further reaffirmed in a novel study design by: 1) the use
of a placebo run-in period, during which patients devel-
oping muscle events will be excluded, and 2) the inclusion
of a blinded statin rechallenge arm of atorvastatin 20 mg/
day in parallel to the blinded ezetimibe and alirocumab
arms. These important controls were lacking from previous
anti-PCSK9 trials in statin intolerant patients.17,18 Hence,
this will be the first study of a new class of LDL-C lowering
agents to prospectively and rigorously identify statin intol-
erant patients. The study allows for the alirocumab dose to
be increased depending on pre-specified LDL-C levels.
ALTERNATIVE is part of the ODYSSEY Phase 3 clinical
trial program, which consists of 14 global trials that involve
more than 23,500 patients from more than 2000 study cen-
ters, as well as a large 18,000 patient CVoutcome trial. The
program is designed to further assess the efficacy and safety
of alirocumab in a range of clinical settings and patient
groups.Methods
ODYSSEY ALTERNATIVE is a randomized, double-
blind, double-dummy, active-controlled, parallel-group
study conducted in 67 sites across the United States, Canada,
Austria, France, Italy, Israel, Norway, and the United
Kingdom. The study was conducted in compliance with
the principles of the Declaration of Helsinki and according
to the International Conference on Harmonisation guidelines
for Good Clinical Practice. The protocols were reviewed and
approved by the institutional review board of each partici-
pating center. A progress report was sent to the relevant
ethics committees at least annually, as was a summary of the
outcome at the end of the trial. All participants were required
to provide written informed consent.
Patients
Patients were eligible to participate if they were aged
$18 years (or legal age of majority), had a documented
history of statin intolerance, and were of moderate, high, or
very high CV risk. Statin intolerance is defined in this study
as the inability to tolerate at least 2 different statins because
of unexplained skeletal muscle-related symptoms, such as
pain, aches, weakness, or cramping that began or increased
during statin therapy and returned to baseline when statin
therapy was discontinued. For each patient to meet this
definition, one of the statins that was discontinued had to
have been at the lowest approved daily starting dose (ie,
rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg,
lovastatin 20 mg, pravastatin 40 mg, fluvastatin 40 mg,
pitavastatin 2 mg); the other statin was at any dose.
Table 1 CV risk categories used for patient selection in this study
CV risk category Criteria
Moderate  Calculated 10-year fatal CVD risk SCORE $1 and ,5%a
High  Calculated 10-year fatal CVD risk SCORE $5%a
 Moderate chronic kidney disease
 Type 1 or type 2 diabetes mellitus without target organ damage
 heFH
Very high  A history of documented CHDb, ischemic stroke, peripheral artery disease, transient ischemic attack,
abdominal aortic aneurysm, or carotid artery occlusion .50% without symptoms
 Carotid endarterectomy or carotid artery stent procedure
 Renal artery stenosis or renal artery stent procedure
 Type 1 or type 2 diabetes mellitus with target organ damage
CHD, coronary heart disease; CV, cardiovascular; CVD, CV disease; heFH, heterozygous familial hypercholesterolemia; SCORE, Systemic Coronary Risk
Estimation.
a10-year CVD risk was calculated using the European SCORE system, which includes calibration by the CVD risk of the country.22,36 For purposes of
calculating SCORE levels in this study, the United States was classified as a high-risk country and Canada as a low-risk country using available CVD mor-
tality data37,38 compared with the cutoffs given in the 2012 European CVD guidelines.36
bDocumented CHD includes acute myocardial infarction, silent myocardial infarction, unstable angina, coronary revascularization procedure
(eg, percutaneous coronary intervention or coronary artery bypass graft surgery), and clinically significant CHD diagnosed by invasive or noninvasive
testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging).
556 Journal of Clinical Lipidology, Vol 8, No 6, December 2014Risk was defined as shown in Table 1. Patients at very
high CV risk were eligible with a calculated serum LDL-
C $70 mg/dL (1.81 mmol/L), whereas those at high or
moderate CV risk were eligible with a calculated serum
LDL-C $100 mg/dL (2.59 mmol/L) at screening. Patients
with heterozygous familial hypercholesterolemia were clas-
sified as high-risk regardless of their Systematic Coronary
Risk Evaluation (SCORE). Diagnosis of heterozygous
familial hypercholesterolemia in this study was made by
genotyping or, if genotyping was not available, by clinical
criteria (investigators could choose to use the Simon
Broome19 or the World Health Organization/Dutch Lipid
Network20 criteria).
Patients had not taken a statin at or above the lowest
approved daily dose within 4 weeks before the screening
visit. However, patients must have been receiving a stable
dose of other lipid-lowering therapy, including ezetimibe,
a bile acid sequestrant, nicotinic acid, omega-3 fatty acids
($1000 mg daily), or fenofibrate, for at least 4 weeks
before screening (6 weeks for fenofibrate). Patients
receiving fibrates other than fenofibrate within 6 weeks
of screening were excluded. Patients who demonstrated
intolerance to statins while on an alternate dosing statin
regimen (eg, 1–3 times weekly) instead of a daily statin
regimen were still considered as statin-intolerant to a daily
dosing regimen and, therefore, eligible to enroll in the
study if their cumulative weekly statin dose was no more
than 7 times the lowest dose and the criteria outlined
previously were met. Patients who experienced unex-
plained skeletal muscle-related AEs during the single-
blind placebo run-in or at randomization were excluded. A
partial list of exclusion criteria is given in Supplementary
Table 1.Study design
The study consisted of 5 to 6 periods (Fig. 1). Patients
were asked to follow a stable diet equivalent to the National
Cholesterol Education Program Adult Treatment Panel III
Therapeutic Lifestyle Changes diet21 during the study.
Patients receiving bile acid sequestrants, nicotinic acid,
fenofibrate, or omega-3 fatty acids before screening could
continue these medications, but ezetimibe, statins, red yeast
rice, or fibrates other than fenofibrate were not allowed dur-
ing the study. After screening, patients entered a 2-week
washout of ezetimibe, statins (for patients taking a nonap-
proved dose or regimen), and red yeast rice. However,
patients were not permitted to receive fibrates (other than
fenofibrate) within 6 weeks of screening, and any patients
receiving fibrates during this time were excluded. Fibrates
such as gemfibrozil can inhibit the metabolism of statins,
thus potentially increasing the risk of muscle-related side
effects; this class of drugs (apart from fenofibrate) was
therefore not allowed in this study. Fenofibrate does not
alter statin pharmacokinetics and thus was allowed.22
Only patients were blinded to treatment during the
4-week, single-blind placebo run-in period when all
patients received subcutaneous (SC) placebo injection
Q2W as well as daily oral placebo. At the end of the
single-blind run-in, patients were randomized to receive
either alirocumab 75 mg SC Q2W and daily oral placebo,
alirocumab SC placebo Q2W and daily oral ezetimibe
10 mg, or alirocumab SC placebo Q2W and daily oral
atorvastatin 20 mg (Fig. 1) using a 2:2:1 permuted-block
randomization. Hence, each treatment arm received an in-
jection (alirocumab or placebo) and an oral dosage form
(single placebo capsule representing both ezetimibe and
Figure 1 Study design of (A) the main part of the ODYSSEYALTERNATIVE study and (B) the open-label extension. Time points for
lipid assessments are indicated by vertical arrows under the schematics. *Eligible patients can opt to participate in a 196-week open-label
treatment period. ATV, atorvastatin; CV, cardiovascular; EZE, ezetimibe; LDL-C, low-density lipoprotein cholesterol; NCEP-ATP III TLC,
National Cholesterol Education Program Adult Treatment Panel III Therapeutic Lifestyle Changes; OLE, open-label extension; PO, orally;
Q2W, every 2 weeks; QD, daily; R, randomization; RYR, red yeast rice; SC, subcutaneously; W, week.
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placebo, ezetimibe, and atorvastatin were overencapsulated
to look identical. Randomization was stratified according to
whether there was documented history of either myocardial
infarction or ischemic stroke. Alirocumab and its pla-
cebo were administered subcutaneously by a prefilled pen
capable of delivering the drug product or placebo in a
1-mL volume. Patients could self-inject or designate
another person to assist them. At the first scheduled visit
of the single-blind placebo run-in period, the patient or
designated person was trained to use the prefilled pen,
and the injection was performed on site.
The alirocumab dose was automatically up-titrated from
75 mg to 150 mg Q2W in a double-blinded fashion at week
12 of the double-blind treatment period, depending on a
patient’s baseline CV risk and LDL-C level at week 8. The
dose was increased for patients at very high CV risk if theirweek 8 LDL-C level was $70 mg/dL (1.81 mmol/L), and
for those at high or moderate CV risk if their week 8
LDL-C level was $100 mg/dL (2.59 mmol/L).
At the end of the 24-week, double-blind treatment
period, patients could choose to enter an open-label period
that was followed by an 8-week off-treatment follow-up
period. Patients who opted not to enter the open-label
period entered an 8-week follow-up period. Patients who
enrolled in the open-label extension underwent assessment
at week 24, the end of the double-blind period (Fig. 1B).
Those entering the open-label extension are receiving
alirocumab 75 mg SC Q2W starting at week 24 of the
double-blind period and continuing for approximately
3 years. The alirocumab dose was increased from 75 mg
to 150 mg Q2W at week 36 of the open-label extension
based on the LDL-C level at week 32 and the judgment
of the investigator.
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The primary efficacy endpoint is the percent change in
LDL-C from baseline to week 24, by intent-to-treat (ITT)
analysis. Secondary endpoints include the change from
baseline to 24 weeks using on-treatment LDL-C values, and
in other atherogenic lipoproteins (Supplementary Table 2).
Efficacy endpoints will be determined for the alirocumab vs
ezetimibe arms only; the atorvastatin arm will only be
included in the safety analysis.
Lipid parameters will be assessed at 0, 4, 8, 12, 16, and
24 weeks of the double-blind period and every 4 weeks
during the open-label extension up to week 36, then at week
52 and every 12 weeks thereafter (Fig. 1B). Lipid parame-
ters will be analyzed by a central laboratory. LDL-C will be
calculated using the Friedewald formula23 at screening and
all time points during the double-blind period. LDL-C will
also be measured via beta quantification at weeks 0 and 24
of the double-blind period and if a patient’s triglycerides
exceed 400 mg/dL (4.52 mmol/L) at any time point.
Safety
An important safety consideration is the number of
withdrawals because of AEs (particularly muscle-related
AEs), which will help to characterize the statin-intolerant
population in this study. The study was designed to
randomize a sufficient number of patients to ensure that
at least 1 withdrawal from an AE in the ezetimibe arm can
be detected (see Statistical Design and Analysis). Muscle-
related AEs are being assessed by both patient self-reports
and AE query at each clinic visit. The study treatments will
be discontinued permanently if the patient, after counseling
by the site study staff, is convinced that prior statin-related
muscle symptoms have been reproduced and that his or her
symptoms may be unduly prolonged by continuing treat-
ment. If muscle symptoms are tolerable, study treatment
can be continued. Patients who prematurely discontinue the
study treatment during the double-blind treatment period
will remain in the study and undergo all remaining
scheduled visits and safety assessments. Within 5 days of
study drug discontinuation, the patient will undergo an
end-of-treatment assessments visit. Subsequent visits will
follow the original planned study schedule until the end of
study.
In this study of patients who are intolerant to statins,
certain AEs commonly associated with statins, including
muscle-related AEs (including myositis) and liver func-
tion–related abnormalities (elevated alanine aminotrans-
ferase levels), will be classed as AEs of special interest, and
will be monitored closely, documented, and managed in a
prespecified manner (whether serious or nonserious).
Myositis is here defined as myalgia (muscle-related AEs)
with creatine phosphokinase elevation between .3 times
and #10 times the upper limit of normal, with the creatine
phosphokinase elevation occurring within 2 weeks of the
onset of muscle symptoms.General safety is being assessed as treatment-emergent
AEs (TEAEs), blood biochemistry, hematology, urinalysis
abnormalities, vital signs, electrocardiogram, and develop-
ment of anti-alirocumab antibodies at the time points given
previously for the lipid assessments. Injection site reactions
will be closely monitored as AEs of special interest. TEAEs
are defined as AEs that develop or worsen during treatment,
regardless of their possible relationship to the study drug.
The TEAE period is the time from first dose of study
treatment to 70 days after the last injection, because
residual alirocumab effects are expected up until this time.
Safety laboratory parameters will be analyzed by a
central laboratory, and anti-alirocumab antibodies will be
determined by the Regeneron Clinical Bioanalysis Group
(Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA)
using a validated nonquantitative, titer-based bridging
immunoassay.
Statistical design and analysis
A sample size of 42 patients in the alirocumab and
ezetimibe treatment groups was calculated to provide 95%
power to detect a difference of 20% between alirocumab
and ezetimibe in mean percent change from baseline to
week 24 in LDL-C, using a 2-sided t-test. This assumes a
common standard deviation of 25% based on a previous
alirocumab trial.12
With the sample size consideration for the safety profile,
the overall study sample size during the double-blind
treatment period will be 250 patients, allocating 100
patients to each of the alirocumab and ezetimibe treatment
arms, and 50 patients to the statin treatment arm. Based on
withdrawal events occurring in approximately 3.3% of
patients in the general hypercholesterolemic population
taking ezetimibe,24 it was calculated that 100 patients in
each treatment arm (alirocumab and ezetimibe) will give
a 96% probability of recording at least 1 withdrawal
because of an AE. If the withdrawal rate in this statin-
intolerant population occurs at a rate that is actually higher
than 3.3%, 100 patients per treatment arm will provide an
even stronger ability to provide an estimate of the with-
drawal rate.
The primary efficacy endpoint will be evaluated in
the ITT population. The ITT population will include all
randomized patients with calculated LDL-C value at
baseline and at least 1 calculated LDL-C value within 1
of the analysis windows up to week 24. Missing data will
be accounted for using a mixed-effect model with repeated
measures approach.25,26 For the ITT analysis, all available
measurements at planned time points from weeks 4 to 24,
regardless of status on- or off-treatment, will be used
(Supplementary Methods). An analysis of the primary
endpoint that assesses the consistency of the treatment ef-
fect across prespecified subgroups will be evaluated. Statis-
tical significance of the primary parameter at the 0.05 alpha
level is required before drawing inferential conclusions
about the first key secondary parameter. A hierarchical
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handle multiplicity for analyzing the key secondary end-
points, which will be tested sequentially in the order given
in Supplementary Table 2. Analysis of the secondary end-
points is described in the Supplementary Methods.
An on-treatment analysis or modified ITT will also be
conducted as the first secondary endpoint, and will include
all randomized and treated patients with a baseline and at
least one LDL-C measurement at 4 to 24 weeks of
treatment as long as the LDL-C samples are obtained while
the patient is receiving the study treatment, including an
additional time period after last study treatment adminis-
tration for residual treatment effect. This endpoint is
reflective of the ability of a therapy to lower LDL-C. For
the on-treatment analysis (modified ITT), all available
measurements from weeks 4 to 24 within the on-
treatment time window will be used in the mixed-effect
model with repeated measures. The safety analysis will
include randomized and treated patients. Safety data will be
analyzed using descriptive statistics. Safety and efficacy in
the open-label extension will be assessed in all patients who
receive at least 1 dose of open-label alirocumab. Statistical
analyses will be conducted using SAS version 9.2 or higher
(SAS Institute Inc., Cary, NC).Results
The trial is being conducted across 8 countries. Between
November 21, 2012, and October 4, 2013, 314 patients
were randomized. This is an ongoing clinical trial with the
double-blind period expected to complete in mid-2014.
Full details of baseline characteristics, patient disposition,
and efficacy and safety results will be available in the
future.Discussion
Muscle complaints are the most common symptom
limiting statin use.2,27 In patients for whom daily statin
dosing is no longer a treatment option, non-statin therapies
are available but only provide approximately a 15 to 20%
reduction in LDL-C,7,22 compared with the 30 to 50% reduc-
tions expected with daily regimens of statins such as atorvas-
tatin 10–80 mg, rosuvastatin 5–40 mg, or simvastatin
20–40 mg.1 Intermittent (non-daily) statin dosing has been
reported to provide LDL-C reductions varying from 12%
to 38%; however, these data are based on results from
observational studies.7,28 In a small, randomized controlled
crossover study in 17 patients with previous statin intoler-
ance, once-weekly dosing with rosuvastatin 5 mg reduced
LDL-C by 12.2% vs 0.4% with placebo; myalgia leading
to discontinuation was experienced by 20% of patients
while receiving rosuvastatin compared with 12% of placebo
patients.29 Two studies of the PCSK9 inhibitor evolocumab
have been reported in statin-intolerant patients; however,
both studies lacked both a placebo run-in period, to excludepatients with non-statin related muscle events, and a statin
control arm.17,18 Large, well-controlled randomized trials
of cholesterol-lowering drugs in patients who are intolerant
to statins have yet to be conducted. One difficulty is that
defining and selecting a truly statin-intolerant population
is challenging. The study described in this report rigorously
defines a statin-intolerant population of patients to investi-
gate a novel LDL-C–lowering therapy.
The specific criteria for statin intolerance used in the
study described in this report are based on discussions with
experts, regulators, and investigators during development of
the study protocol. The definition used is also in agreement
with published guidance.2,16 The described study includes a
4-week run-in period in which patients will only receive
single-blind placebo. Patients reporting muscle symptoms
during this period will not be randomized, because those
symptoms will be assumed to be non-statin–related. This
is to help to mitigate the impact of patients with non-
statin–induced muscle issues on the study. Also in the
described study, patients will receive atorvastatin 20 mg/
day if randomized to the statin rechallenge arm to provide
further evidence that the patient population is statin intol-
erant. The 20-mg dose of atorvastatin was chosen after dis-
cussion with experts, who were of the opinion that it
represents a dose that would elicit muscle symptoms
upon rechallenge, but would not preclude patients from
enrolling. Although the statin rechallenge arm will likely
be associated with an increased risk of muscle-related
AEs, it was determined by regulators to be an essential con-
trol for this study to define the appropriate patient popula-
tion. In addition, the 3-year open-label extension is
designed to provide further efficacy and safety information
on alirocumab in this particular population.
Treating hypercholesterolemia in patients who are
intolerant to statins can be difficult because there are few
effective alternative treatments. Ezetimibe was chosen as a
comparator in the present study because it is a recom-
mended option for statin-intolerant patients from its favor-
able safety profile.19 Ezetimibe reduces LDL-C levels by
15 to 20%30–32 and, in the absence of statins, requires other
agents to produce the magnitude of LDL-C reduction at-
tained with statins. These additional agents, such as niacin
and bile acid sequestrants, cause additional (albeit non–
muscle-related) symptoms, which make their use diffi-
cult.1,22 At the same time, the magnitude of LDL-C
reduction with statin treatment is not correlated with
increased rates of muscle complaints, although the risk of
myopathy is increased for very high doses of some sta-
tins.33,34 For example, high doses (80 mg) of simvastatin
are no longer recommended by the Food and Drug Admin-
istration because of concerns over an increased risk of
myopathy.35 Clearly, there is a need to develop additional
cholesterol-lowering therapies for patients with statin intol-
erance. Alirocumab may have the potential to meet this
need, because it reduces LDL-C levels by approximately
50% when used as monotherapy, and has so far shown a
safety profile comparable with ezetimibe or placebo.12–15
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